At the time of writing, Rocket Pharmaceuticals Inc [RCKT] stock is trading at $2.88, down -2.04%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RCKT shares have lost -12.73% over the last week, with a monthly amount drifted -27.64%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rocket Pharmaceuticals Inc [NASDAQ: RCKT] stock has seen the most recent analyst activity on November 18, 2025, when JP Morgan downgraded its rating to a Underweight. Previously, BofA Securities upgraded its rating to Buy on August 20, 2025, and kept the price target unchanged to $10. On July 25, 2025, downgrade downgraded it’s rating to Neutral but maintained its price target of $4 on the stock. Evercore ISI downgraded its rating to a In-line but stick to its price target of $5 on May 30, 2025. Morgan Stanley downgraded its rating to a Equal-Weight but $7 remained the price target by the analyst firm on May 28, 2025. Leerink Partners downgraded its rating to Market Perform for this stock on May 28, 2025, but kept the price target unchanged to $8. In a note dated May 28, 2025, JP Morgan downgraded a Neutral rating on this stock.
For the past year, the stock price of Rocket Pharmaceuticals Inc fluctuated between $2.19 and $15.01. Currently, Wall Street analysts expect the stock to reach $3.83 within the next 12 months. Rocket Pharmaceuticals Inc [NASDAQ: RCKT] shares were valued at $2.88 at the most recent close of the market. An investor can expect a potential return of 32.99% based on the average RCKT price forecast.
Analyzing the RCKT fundamentals
Gross Profit Margin for this corporation currently stands at -0.1% with Operating Profit Margin at -27.27%, Pretax Profit Margin comes in at -26.23%, and Net Profit Margin reading is -26.23%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -0.62 and Total Capital is -0.74. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.84 points at the first support level, and at 2.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.95, and for the 2nd resistance point, it is at 3.01.
Ratios To Look Out For
It is important to note that Rocket Pharmaceuticals Inc [NASDAQ:RCKT] has a current ratio of 7.30. In addition, the Quick Ratio stands at 7.30 and the Cash Ratio stands at 2.44.
Transactions by insiders
Recent insider trading involved Schwartz Jonathan David, Officer, that happened on Nov 18 ’25 when 2545.0 shares were purchased. Officer, Shah Gaurav completed a deal on Nov 18 ’25 to buy 6276.0 shares. Meanwhile, Officer Militello John bought 1086.0 shares on Nov 18 ’25.
